Metastatic Colorectal Cancer: Future Directions in Care
Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.
Read More
Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials
Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.
Read More
Combination IO/TKI Strategies in Metastatic Colorectal Cancer
A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.
Read More
Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy
A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.
Read More
Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer
Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.
Read More
Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer
Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.
Read More
Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial
Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial
Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.
Read More
Importance of Identifying HER2 Status in Metastatic Colorectal Cancer
Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.
Read More
Role of Tucatinib in HER2+ mCRC
Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.
Read More